-
公开(公告)号：US20190316090A1
公开(公告)日：2019-10-17
申请号：US16426880
申请日：2019-05-30
IPC分类号： C12N5/078 , A61K31/7088 , A61K9/00 , A61K38/17 , A61K9/50 , A61K47/69 , A61K39/385 , A61K39/00 , C07K16/08 , C12N9/88 , A61K35/18
摘要： Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
-
公开(公告)号：US11576934B2
公开(公告)日：2023-02-14
申请号：US16383236
申请日：2019-04-12
发明人： Jordi Mata-Fink , John Round , Noubar B. Afeyan , Avak Kahvejian
摘要： Provided are cells containing exogenous antigen and uses thereof.
-
公开(公告)号：US20210180015A1
公开(公告)日：2021-06-17
申请号：US17072611
申请日：2020-10-16
发明人： Jordi Mata-Fink , Avak Kahvejian
摘要： Composition comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
-
公开(公告)号：US20220073875A1
公开(公告)日：2022-03-10
申请号：US17529686
申请日：2021-11-18
发明人： Qin Yu , Urjeet Khanwalkar , Omid Harandi , Ewan Dunn , Tanyaporn Pattarabanjird , Avak Kahvejian , Jordi Mata-Fink
IPC分类号： C12N5/078 , C07K14/18 , C12N15/113 , C12N15/86 , C12N15/69 , C12N5/0789
摘要： This disclosure provides, among other things, amplifiable nucleic acid constructs for expressing a gene of interest in a cell, e.g., an erythroid cell. The amplifiable nucleic acid construct may contain the gene of interest and an RNA-dependent RNA polymerase (RdRP)-responsive 5′ UTR, and may optionally further contain an RdRP-responsive 3′ UTR. RdRP may also be provided, e.g., on the same construct or a different construct.
-
公开(公告)号：US11141433B2
公开(公告)日：2021-10-12
申请号：US16297540
申请日：2019-03-08
IPC分类号： A61K35/17 , A61P35/00 , A61K35/18 , A61K38/17 , A61K38/19 , A61K38/20 , A61K38/30 , C12N5/078 , C12N5/0783 , C12N15/86 , A61K39/00 , C07K14/705 , A61K39/395 , A61K47/68
摘要： The present disclosure relates to erythroid cells that have been engineered to include, e.g., at the surface of the cell, one or more exogenous stimulatory polypeptides, wherein the exogenous stimulatory polypeptides presented are sufficient to stimulate an immune killer cell. The engineered enucleated cells of the present disclosure are useful in methods of activating NK cells and/or CD8+T-cells in a subject in need thereof, such as subjects having cancer or an infectious disease, and in particular cancers or infectious diseases characterized by downregulation of MHC Class I presentation.
-
公开(公告)号：US20210246426A1
公开(公告)日：2021-08-12
申请号：US16889783
申请日：2020-06-01
摘要： The present disclosure relates to engineered erythroid cells and enucleated cells that include one or more of exogenous HLA-G polypeptides, exogenous immunogenic polypeptides, and exogenous coinhibitory polypeptides wherein the cells are capable of inducing immune tolerance and/or reducing immune response to the exogenous immunogenic polypeptides when administered to a subject.
-
公开(公告)号：US11020435B2
公开(公告)日：2021-06-01
申请号：US15932341
申请日：2018-02-16
发明人： Tom Wickham , Tiffany F. Chen , Xuqing Zhang , Carolyn Sayre , Jordi Mata-Fink , Sivan Elloul , Billy Law , Lenka Hoffman , Kristian Eric Teichert , Shamael Rabia Dastagir
IPC分类号： A61K35/18 , C12N5/078 , A61K39/385 , A61K39/00 , A61K38/17
摘要： Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.
-
公开(公告)号：US10568910B2
公开(公告)日：2020-02-25
申请号：US15906873
申请日：2018-02-27
发明人： Avak Kahvejian , Jordi Mata-Fink , Robert J. Deans , Tiffany F. Chen , John Round , Noubar B. Afeyan , Torben Straight Nissen , Nathan Dowden , Tom Wickham , Sivan Elloul
IPC分类号： A61K35/18 , A61K35/12 , A61K38/19 , A61K39/00 , A61K39/395 , C12N5/078 , A61P17/00 , C07K14/705
摘要： The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having a cancer.
-
公开(公告)号：US20220088076A1
公开(公告)日：2022-03-24
申请号：US17486537
申请日：2021-09-27
IPC分类号： A61K35/17 , A61P35/00 , A61K35/18 , A61K38/17 , A61K38/19 , A61K38/20 , A61K38/30 , C12N5/078 , C12N5/0783 , C12N15/86 , A61K39/00 , C07K14/705 , A61K39/395
摘要： The present disclosure relates to erythroid cells that have been engineered to include, e.g., at the surface of the cell, one or more exogenous stimulatory polypeptides, wherein the exogenous stimulatory polypeptides presented are sufficient to stimulate an immune killer cell. The engineered enucleated cells of the present disclosure are useful in methods of activating NK cells and/or CD8+ T-cells in a subject in need thereof, such as subjects having cancer or an infectious disease, and in particular cancers or infectious diseases characterized by downregulation of MHC Class I presentation.
-
10.发明申请公开(公告)号：US20220072048A1
公开(公告)日：2022-03-10
申请号：US17528422
申请日：2021-11-17
发明人： Avak Kahvejian , Jordi Mata-Fink , Robert J. Deans , Tiffany F. Chen , John Round , Noubar B. Afeyan , Torben Straight Nissen , Nathan Dowden , Tom Wickham
IPC分类号： A61K35/18 , A61K35/12 , A61K38/19 , A61K39/00 , A61K39/395 , C12N5/078 , A61P17/00 , C07K14/705
摘要： The invention includes compositions and methods related to multimodal therapies, e.g., for treating immune conditions. A multimodal therapy described herein provides and/or administers a plurality of agents that function in a coordinated manner to provide a therapeutic benefit to a subject in need thereof, e.g., a subject having an autoimmune disease or inflammatory disease.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.025 秒)
